#1 Clinical Trials Search in Europe

Rezvilutamide

Rezvilutamide is an emerging drug being studied in clinical trials for the treatment of prostate cancer. This article explores the ongoing research into rezvilutamide’s efficacy and safety for various stages of prostate cancer, including metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk localized disease. We’ll examine how rezvilutamide is being evaluated alone and in combination with other therapies to potentially improve outcomes for prostate cancer patients.

Table of Contents

What is Rezvilutamide?

Rezvilutamide, also known as SHR3680, is a novel hormonal therapy drug that belongs to a class of medications called androgen receptor inhibitors[1]. It is currently being studied as a promising treatment for various stages of prostate cancer. Rezvilutamide works by targeting and blocking the androgen receptor, which plays a crucial role in the growth and spread of prostate cancer cells[2].

What Conditions Does Rezvilutamide Treat?

Rezvilutamide is being investigated for the treatment of several prostate cancer conditions, including:

  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): This is a type of prostate cancer that has spread beyond the prostate gland but still responds to hormone therapy[2].
  • Locally Advanced Prostate Cancer: Cancer that has grown outside the prostate gland but hasn’t spread to other parts of the body[3].
  • Oligometastatic Prostate Cancer: A condition where the cancer has spread, but only to a limited number of sites[3].
  • Biochemical Recurrence: This occurs when prostate-specific antigen (PSA) levels rise after initial treatment, indicating possible cancer recurrence[1].

How Does Rezvilutamide Work?

Rezvilutamide works by blocking the androgen receptor in prostate cancer cells. Androgens, such as testosterone, are male hormones that can stimulate the growth of prostate cancer. By inhibiting the androgen receptor, Rezvilutamide helps to slow down or stop the growth of cancer cells[4].

This medication is often used in combination with other treatments, such as:

  • Androgen Deprivation Therapy (ADT): A treatment that reduces the levels of male hormones in the body[2].
  • Docetaxel: A chemotherapy drug used to kill cancer cells[2].
  • Abiraterone: Another hormone therapy that works differently from Rezvilutamide[4].

How is Rezvilutamide Administered?

Rezvilutamide is typically taken orally in tablet form. The common dosage is 240 mg (three 80 mg tablets) once daily, which can be taken with or without food[5]. However, the exact dosage and duration of treatment may vary depending on the specific condition being treated and the individual patient’s needs. It’s important to follow the prescribing doctor’s instructions carefully.

Current Clinical Trials

Rezvilutamide is currently being studied in several clinical trials to evaluate its effectiveness and safety in different scenarios:

  • Comparing Rezvilutamide + ADT + Docetaxel versus Rezvilutamide + ADT in metastatic hormone-sensitive prostate cancer[2].
  • Using Rezvilutamide alone or in combination with Abiraterone for patients who have progressed after prior therapy[4].
  • Evaluating Rezvilutamide in combination with ADT for high-risk salivary duct carcinoma, a rare type of cancer[5].
  • Studying Rezvilutamide with ADT and salvage radiation therapy for patients with biochemical recurrence after prostate surgery[1].

Potential Side Effects

As with any medication, Rezvilutamide may cause side effects. While specific side effects for Rezvilutamide are still being studied in clinical trials, common side effects of similar drugs in its class may include:

  • Fatigue
  • Hot flashes
  • Decreased appetite
  • Diarrhea
  • Nausea

It’s important to note that not everyone experiences side effects, and they can vary from person to person. Patients should report any unusual symptoms to their healthcare provider[6].

Future Research and Potential

Ongoing research is exploring new ways to use Rezvilutamide effectively:

  • Timing of Administration: A study is investigating whether taking Rezvilutamide in the evening versus the morning affects its efficacy and safety[6].
  • Neoadjuvant Therapy: Researchers are studying the use of Rezvilutamide before surgery (neoadjuvant therapy) in high-risk and locally advanced prostate cancer[7].
  • Combination Therapies: Various trials are exploring how Rezvilutamide works in combination with other treatments to potentially enhance its effectiveness[3].

As research continues, Rezvilutamide shows promise in becoming an important tool in the treatment of prostate cancer, potentially offering new hope for patients with various stages of the disease.

Aspect Details
Drug Name Rezvilutamide (also known as SHR3680)
Drug Class Novel hormonal therapy, androgen receptor inhibitor
Main Indications Metastatic hormone-sensitive prostate cancer (mHSPC), high-risk localized prostate cancer, biochemically recurrent prostate cancer
Common Dosage 240 mg (3 x 80 mg tablets) orally once daily
Combination Therapies Androgen deprivation therapy (ADT), docetaxel, abiraterone, radiation therapy
Key Outcome Measures Overall survival, progression-free survival, PSA response, time to castration resistance, quality of life, pathological response
Notable Trial Designs Neoadjuvant therapy before surgery, combination with other novel hormonal agents, comparison of morning vs evening dosing
Potential Advantages May improve outcomes in combination with other therapies, being studied in various stages of prostate cancer

FAQ

  • What is rezvilutamide? Rezvilutamide is a novel hormonal therapy drug being studied for the treatment of prostate cancer. It belongs to a class of medications called androgen receptor inhibitors, which work by blocking the effects of male hormones (androgens) on prostate cancer cells.
  • What types of prostate cancer is rezvilutamide being studied for? Rezvilutamide is being investigated for various stages of prostate cancer, including metastatic hormone-sensitive prostate cancer (mHSPC), high-risk localized prostate cancer, and biochemically recurrent prostate cancer after initial treatment.
  • How is rezvilutamide given to patients in clinical trials? In most clinical trials, rezvilutamide is given as an oral medication, typically at a dose of 240 mg (three 80 mg tablets) taken once daily. It can usually be taken with or without food.
  • What other treatments is rezvilutamide being combined with in trials? Rezvilutamide is being studied in combination with various other treatments, including androgen deprivation therapy (ADT), docetaxel chemotherapy, abiraterone, radiation therapy, and surgical procedures like radical prostatectomy.
  • What are some of the main outcomes being measured in rezvilutamide trials? Key outcomes being evaluated include overall survival, progression-free survival, PSA response rates, time to castration resistance, quality of life measures, and safety/side effect profiles. Some trials are also looking at pathological responses after surgery.

Ongoing Clinical Trials on Rezvilutamide

  • Study Comparing Rezvilutamide and Bicalutamide with Hormone Therapy for Patients with Advanced Prostate Cancer

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Poland

Glossary

  • Metastatic hormone-sensitive prostate cancer (mHSPC): Prostate cancer that has spread beyond the prostate to other parts of the body, but still responds to treatments that lower testosterone levels.
  • Androgen deprivation therapy (ADT): Treatment that reduces levels of male hormones (androgens) in the body to slow the growth of prostate cancer.
  • Prostate-specific antigen (PSA): A protein produced by the prostate gland. PSA levels in the blood are often elevated in men with prostate cancer and are used to monitor treatment response.
  • Castration-resistant prostate cancer (CRPC): Prostate cancer that continues to grow despite treatments to lower testosterone levels.
  • Biochemical recurrence: A rise in PSA levels after initial prostate cancer treatment, suggesting the cancer may be returning.
  • Radical prostatectomy: Surgery to remove the entire prostate gland and surrounding tissues.
  • Salvage radiation therapy (SRT): Radiation treatment given after initial prostate cancer therapy (usually surgery) when there are signs the cancer may be returning.
  • Neoadjuvant therapy: Treatment given before the main treatment (usually surgery) to try to shrink the cancer and make the primary treatment more effective.
  • Circulating tumor cells (CTCs): Cancer cells that have detached from a tumor and entered the bloodstream. They can be used as a biomarker to monitor cancer progression and treatment response.
  • PSMA PET/CT: A specialized imaging technique that combines positron emission tomography (PET) with computed tomography (CT) to detect prostate cancer cells throughout the body.

References

  1. https://clinicaltrials.gov/study/NCT05753566
  2. https://clinicaltrials.gov/study/NCT05983783
  3. https://clinicaltrials.gov/study/NCT06387056
  4. https://clinicaltrials.gov/study/NCT06134271
  5. https://clinicaltrials.gov/study/NCT06348264
  6. https://clinicaltrials.gov/study/NCT06505278
  7. https://clinicaltrials.gov/study/NCT05406999